Intas Pharmaceuticals Limited

Astron Research Limited

Ashish Sehgal

Rikin Patel

Piyush Kansagra

Balvir Singh

Mayank Saxena

Satyavan Dhavale

Kavan Pandya

Jayanta Kumar Mandal

Pallerla Bhaskar

Mahendra Patel

Samir Shah

Priyank Patel

Keyur Patel

Sanjay Dash

Kuldeep Dilip Karnik

Dhara Parikh

Bhavesh Vallabhabhai Patel

Mayur Patel

Aditya Patel

Disclosed are stable extended release formulations and pharmaceutical compositions of Clozapine that exhibit improved stability under a variety of conditions, as well as processes for the preparation of such formulations and compositions.

Stable extended release pharmaceutical composition of clozapine

An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Extended release pharmaceutical composition of Clozapine

Disclosed is an extended release pharmaceutical composition of Clozapine, which can be provided as a reservoir type dosage form, and when dosed to a patient once daily achieves at steady state, AUC, Cand Cin patient plasma that are within 80 to 125% bioequivalence criteria compared to immediate release Clozapine dosed at the same total daily dose divided twice per day. Further, the pharmaceutical composition of Clozapine can provide once daily dosing regimen in order to improve patient compliance and reduces side effects in patients in need thereof. The pharmaceutical composition further lacks any significant food effect on oral administration.

Extended release pharmaceutical composition of clozapine

This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Pharmaceutical composition having improved content uniformity

The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3-6.

Stable tigecycline composition

The present disclosure relates to an in vitro method for measuring the Tof reduction kinetics of iron from Feto Fein an iron-sucrose complex and hence assessing the bioequivalency of iron-sucrose composition. According to the disclosed method, Tof reduction kinetics of iron in an iron-sucrose complex in between 25 to 50 minutes indicates bioequivalent iron-sucrose composition.

In-vitro method for testing bioequivalence of iron-sucrose formulation

Growing community of inventors

Ahmedabad, India

Ashish Sehgal